Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference
November 11, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 16:05 ET
|
Clearside Biomedical, Inc.
- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2 Trials Using SCS Microinjector® Ongoing...
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020
October 30, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina
September 23, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery
September 11, 2020 08:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe
August 26, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 10, 2020 16:05 ET
|
Clearside Biomedical, Inc.
- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) -- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs -- Engaged New Contract Manufacturer for...
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space
August 10, 2020 16:02 ET
|
Clearside Biomedical, Inc.
- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 - ALPHARETTA, Ga., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a...
Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020
July 30, 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...